Laura J. Schumacher - Feb 17, 2022 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role: Vice Chairman
Signature: Steven L. Scrogham, attorney-in-fact for Laura J. Schumacher
Stock symbol: ABBV
Transactions as of: Feb 17, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/22/2022, 04:33 PM
Previous filing: Dec 23, 2021
Next filing: Mar 1, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+51.2K	+25.99%	$0.00	248K	Feb 17, 2022	Direct	F1
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+11.1K	+4.48%	$0.00	259K	Feb 17, 2022	Direct	F2
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+17.5K	+6.73%	$0.00	277K	Feb 17, 2022	Direct	F3
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+11.6K	+4.18%	$0.00	288K	Feb 17, 2022	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABBV	Option (Right to Buy)	Award	$0	+56.9K		$0.00	56.9K	Feb 17, 2022	Common Stock	56.9K	$144.54	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
F2	Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
F3	Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
F4	Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
F5	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,973 on February 17, 2023, 18,972 on February 17, 2024, and 18,972 on February 17, 2025.